Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
Zaihua Zhu, Yu Xue, Tianshu Chu, Jiankang Hu, Wei Gou, Ning Zhang, Juan Li, Jing Yu, Rongping Li, Rongbin Li, Long Qian, Xinwang Duan, Lihua Duan, Qian Xu, Fei Gu, Yuling Lian, Xu Zhang, Hejian Zou
Adv Ther 10.1007/s12325-026-03611-6
摘要
摘要
INTRODUCTION: Patients with recurrent acute gout flares who are unable to use nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine have limited alternatives and remain at high risk of flare recurrence. Firsekibart is a fully human monoclonal antibody targeting interleukin-1βeta (IL-1β) The objective of this study is to evaluate the longer-term efficacy and safety of firsekibart through 48 weeks in patients with acute gout unsuitable for standard anti-inflammatory therapy. METHODS: This was a multicenter, randomized, double-blind, positive-controlled phase 3 study of firsekibart with compound betamethasone. Followed by a 24-week open-label extension (OLE), conducted at hospitals in China. The double-blind phase was conducted from Week 0 to Week 24, followed by an OLE through Week 48 and a 12-week safety follow-up period after the last dose. Adults with ≥ 2 acute gout flares in the past year and a contraindication, intolerance, or inadequate response to NSAIDs and/or colchicine were enrolled. Patients completing the double-blind phase entered the OLE, during which firsekibart was administered for acute gout flares as needed. Efficacy included proportion of patients experiencing ≥ 1 gout flare recurrence, number of flares per patient, and time to first recurrence through Week 48, as well as rescue medication use during the OLE. Exploratory outcomes included health-related quality of life and flare-related pain. Safety included adverse events (AEs), laboratory tests, and immunogenicity. RESULTS: Of 313 patients (double-blind phase), 300 entered the OLE. By week 48, gout flare recurrence occurred in 70 patients (44.9%) in the firsekibart group compared with 116 (74.8%) in the positive control group (difference - 29.97%; 95% CI - 40.228% to - 18.544%). Kaplan-Meier analysis showed that the median time to first recurrence was not reached with firsekibart versus 37 days with positive control, indicating a 70% [hazard ratio (HR) 0.30; 95% confidence interval (CI) 0.223, 0.408; stratified log rank P < 0.0001] lower recurrence risk. Firsekibart maintained efficacy through Week 48. Treatment-emergent adverse events were reported in 89.7% of patients in the firsekibart group and 89.1% in the positive control group, with no new safety signals identified during extended follow-up. CONCLUSION: In this open-label extension study, firsekibart demonstrated sustained efficacy in reducing gout flare recurrence through 48 weeks, with a consistent and favorable safety profile, and no new safety signals identified during extended follow-up. TRIAL REGISTRATION: NCT05983445.
KM 提取结果
0 个 Figure · 0 个 KM 面板